PALO ALTO, Calif.--(BUSINESS WIRE)--March 7, 2006--Connetics Corporation (Nasdaq:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, today announced it has obtained an exclusive, worldwide license to certain patented technology that has potential utility in the treatment of hyperhidrosis. Connetics has initiated a formulation development program utilizing this technology with the goal of developing a safe, effective, well-tolerated and cosmetically elegant topical formulation. The Company intends to begin clinical development immediately after completion of the formulation development activities. Financial terms include upfront, milestone and royalty payments.
